Investigation Report on China Sildenafil Market, 2010-2019
|発行||China Research and Intelligence||商品コード||297277|
|出版日||ページ情報||英文 20 Pages
|中国のシルデナフィル市場の分析 Investigation Report on China Sildenafil Market, 2010-2019|
|出版日: 2015年05月28日||ページ情報: 英文 20 Pages||
世界各国で数億人の男性が勃起不全(ED)に苦しみ、中国でも5000万人以上のED患者が存在します。この巨大な市場を目指して、世界各国の企業がED治療薬の開発を進めています。Pfizer Co., Ltd.が開発したシルデナフィル(Sildenafil)は、当初はPDE5の阻害薬として開発されましたが、治験の結果むしろEDへの治療効果が認められ、「バイアグラ」の商品名で1998年に米国FDA（食品医薬品局）の認証を獲得しました。同年には中国でも上市され、現在まで継続的に売上高を拡大しています。2014年からはジェネリック医薬品も登場し始めるため、今後は価格の引き下げが見込まれていますが、EDの患者数自体は増加し続けるため、シルデナフィルの市場規模は今後も成長し続けるものと思われます。
Hundreds of millions of adult men suffer from erectile dysfunction (ED) throughout the world and there are also over 50 million ED patients in China. It is shown that among men aged above 35, over 60% suffer from different degrees of ED, among which 50% is due to pure organogenic pathogeny, 30% pure psychogenic factors and 20% both of the former two. Men with ED are prone to sense of inferiority and depression, which influence their emotions and life gravely. Therefore, the sexual dysfunction of adult men can't be ignored. Hence many drug makers' close attention to the drug market of ED.
Sildenafil, developed by Pfizer, has a main indication of ED and other indications like pulmonary hypertension and altitude sickness.
Pfizer sought patent for Viagra from China's State Intellectual Property Office in 1994 and succeed. The Patent Law of China formulates that the valid term for a patent is 20 years, therefore, Viagra's patent shall expire in 2014. During the 20 years, Sildenafil (trade name Viagra) basically monopolized Chinese market. With the expiry of Virgra patent, Sildenafil made by local enterprises is expected to get a slice of Chinese market. According to CRI's survey on sample hospitals, after entering China in 1998, Viagra showed no sudden explosion with a CAGR of about 13.1% during the period of 2006-2014. According to CRI, the main reason lies in this: since Viagra could also be bought without prescription in many pharmacies despite its status as prescription drug as a result of loose control, its sales growth mainly comes from pharmacies instead of hospitals. Viagra has occupied an important position among drugs for sexual dysfunction for a long time in China, therefore many local firms start to make generic drugs in succession. Although Viagra's price will drop as generic drugs start to appear in the Chinese market, Pfizer's market share will still go down for the price of generic drugs made by local firms is lower.
According to CRI's survey, the retail price of Viagra made by Pfizer in China exceeds 100 CNY/pill (100 ml), but that in America is about 8 USD/pill which is equivalent to less than 50 CNY/pill.
In 2004, Pfizer's Viagra was qualified to enter Chinese retail pharmacies. Similar drugs in the market like Bayer's Levitra (Vardenafil) got such qualification in 2006 and Lilly's Cialis (Tadalafil) in 2007.
As the patent protection of Viagra all over the world start to expire, its market share will gradually decrease. A good case in point is the Korean market where up to 28 kinds of generic drugs with different forms and dosages appeared the day after the expiry of Viagra's patent in Korea on May.17, 2012. Since the price of such generic drugs equals only one third of Viagra's price, the sales value of Viagra in that month fell by more than 40% compared with the same period of last year. After Viagra's patent expired, pharmaceutical companies can produce Sildenafil as long as they get complete approval. In Oct. 2014, sildenafil citrate (trade name Jin Ge) made by Guangzhou Bai Yun Shan Pharmaceutical General Factory hit the market. According to the statistics of CRI, by May. 2015, Jiangsu Lianhuan Pharmaceutical Co., Ltd, Sichuan Yuanji Pharmaceutical Pharmaceutical Co., Ltd, the Biochemical Pharmaceutical Factory of Zhuhai SEZ and Beijing Midsky Kangda Medicine Technology Co., Ltd have all applied for the approval of generic drugs of Viagra.
With the economic development, the change of life styles and the increased psychological pressures, the number of ED patients will keep growing in the next few years in China. Besides, as Sildenafil is estimated to add new indications to current ones, its market size will keep growing in the next few years in China.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: